129 related articles for article (PubMed ID: 7658452)
1. Synthesis and evaluation of 5-amino-5,6,7,8-tetrahydroquinolinones as potential agents for the treatment of Alzheimer's disease.
Fink DM; Bores GM; Effland RC; Huger FP; Kurys BE; Rush DK; Selk DE
J Med Chem; 1995 Sep; 38(18):3645-51. PubMed ID: 7658452
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Badia A; Baños JE; Camps P; Contreras J; Görbig DM; Muñoz-Torrero D; Simón M; Vivas NM
Bioorg Med Chem; 1998 Apr; 6(4):427-40. PubMed ID: 9597187
[TBL] [Abstract][Full Text] [Related]
3. Japanese Huperzia serrata extract and the constituent, huperzine A, ameliorate the scopolamine-induced cognitive impairment in mice.
Ohba T; Yoshino Y; Ishisaka M; Abe N; Tsuruma K; Shimazawa M; Oyama M; Tabira T; Hara H
Biosci Biotechnol Biochem; 2015; 79(11):1838-44. PubMed ID: 26059088
[TBL] [Abstract][Full Text] [Related]
4. Effects of NIK-247 on cholinesterase and scopolamine-induced amnesia.
Kojima J; Nakajima K; Ochiai M; Nakayama K
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):245-51. PubMed ID: 9228650
[TBL] [Abstract][Full Text] [Related]
5. Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer's Disease.
Friedli MJ; Inestrosa NC
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770940
[TBL] [Abstract][Full Text] [Related]
6. 9-Amino-1,2,3,4-tetrahydroacridin-1-ols: synthesis and evaluation as potential Alzheimer's disease therapeutics.
Shutske GM; Pierrat FA; Kapples KJ; Cornfeldt ML; Szewczak MR; Huger FP; Bores GM; Haroutunian V; Davis KL
J Med Chem; 1989 Aug; 32(8):1805-13. PubMed ID: 2754707
[TBL] [Abstract][Full Text] [Related]
7. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease.
Camps P; Cusack B; Mallender WD; El Achab RE; Morral J; Muñoz-Torrero D; Rosenberry TL
Mol Pharmacol; 2000 Feb; 57(2):409-17. PubMed ID: 10648652
[TBL] [Abstract][Full Text] [Related]
8. Potent, easily synthesized huperzine A-tacrine hybrid acetylcholinesterase inhibitors.
Carlier PR; Du DM; Han Y; Liu J; Pang YP
Bioorg Med Chem Lett; 1999 Aug; 9(16):2335-8. PubMed ID: 10476864
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, in vitro pharmacology, and molecular modeling of very potent tacrine-huperzine A hybrids as acetylcholinesterase inhibitors of potential interest for the treatment of Alzheimer's disease.
Camps P; El Achab R; Görbig DM; Morral J; Muñoz-Torrero D; Badia A; Eladi Baños J; Vivas NM; Barril X; Orozco M; Luque FJ
J Med Chem; 1999 Aug; 42(17):3227-42. PubMed ID: 10464010
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and evaluation of novel heterodimers of donepezil and huperzine fragments as acetylcholinesterase inhibitors.
Hu Y; Zhang J; Chandrashankra O; Ip FC; Ip NY
Bioorg Med Chem; 2013 Feb; 21(3):676-83. PubMed ID: 23273608
[TBL] [Abstract][Full Text] [Related]
11. Huperzine A--an interesting anticholinesterase compound from the Chinese herbal medicine.
Patocka J
Acta Medica (Hradec Kralove); 1998; 41(4):155-7. PubMed ID: 9951045
[TBL] [Abstract][Full Text] [Related]
12. Development of 2-Methoxyhuprine as Novel Lead for Alzheimer's Disease Therapy.
Mezeiova E; Korabecny J; Sepsova V; Hrabinova M; Jost P; Muckova L; Kucera T; Dolezal R; Misik J; Spilovska K; Pham NL; Pokrievkova L; Roh J; Jun D; Soukup O; Kaping D; Kuca K
Molecules; 2017 Jul; 22(8):. PubMed ID: 28788095
[TBL] [Abstract][Full Text] [Related]
13. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates.
Dvir H; Wong DM; Harel M; Barril X; Orozco M; Luque FJ; Muñoz-Torrero D; Camps P; Rosenberry TL; Silman I; Sussman JL
Biochemistry; 2002 Mar; 41(9):2970-81. PubMed ID: 11863435
[TBL] [Abstract][Full Text] [Related]
14. Natural and synthetic Huperzine A: effect on cholinergic function in vitro and in vivo.
Hanin I; Tang XC; Kindel GL; Kozikowski AP
Ann N Y Acad Sci; 1993 Sep; 695():304-6. PubMed ID: 8239300
[TBL] [Abstract][Full Text] [Related]
15. Huperzine A--a potent acetylcholinesterase inhibitor of use in the treatment of Alzheimer's disease.
Geib SJ; Tückmantel W; Kozikowski AP
Acta Crystallogr C; 1991 Apr; 47 ( Pt 4)():824-7. PubMed ID: 1863425
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease.
Sang Z; Qiang X; Li Y; Yuan W; Liu Q; Shi Y; Ang W; Luo Y; Tan Z; Deng Y
Eur J Med Chem; 2015 Apr; 94():348-66. PubMed ID: 25778991
[TBL] [Abstract][Full Text] [Related]
17. New cyclopentaquinoline hybrids with multifunctional capacities for the treatment of Alzheimer's disease.
Czarnecka K; Girek M; Maciejewska K; Skibiński R; Jończyk J; Bajda M; Kabziński J; Sołowiej P; Majsterek I; Szymański P
J Enzyme Inhib Med Chem; 2017 Dec; 33(1):158-170. PubMed ID: 29210299
[TBL] [Abstract][Full Text] [Related]
18. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies.
Ha GT; Wong RK; Zhang Y
Chem Biodivers; 2011 Jul; 8(7):1189-204. PubMed ID: 21766442
[TBL] [Abstract][Full Text] [Related]
19. Delineating the pharmacophoric elements of huperzine A: importance of the unsaturated three-carbon bridge to its AChE inhibitory activity.
Kozikowski AP; Miller CP; Yamada F; Pang YP; Miller JH; McKinney M; Ball RG
J Med Chem; 1991 Dec; 34(12):3399-402. PubMed ID: 1766006
[No Abstract] [Full Text] [Related]
20. [Studies on analogues of huperzine A for treatment of senile dementia. VI. Asymmetric total synthesis of 14-nor-huperzine A and its inhibitory activity of acetylcholinesterase].
He XC; Yu GL; Bai DL
Yao Xue Xue Bao; 2003 May; 38(5):346-9. PubMed ID: 12958837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
